

**IND SAFETY REPORT: INITIAL WRITTEN REPORT****TO: Division of Drug Oncology Products, Center for Drug Evaluation and Research, FDA****FAX: 301-796-9845**

1. IND NUMBER

**70116****58443**

2. AGENT NAME

**CC-5013 (lenalidomide, Revlimid®)****PS-341 (bortezomib; Velcade®)**

3. DATE

**February 24, 2009**

4. SPONSOR

**Division of Cancer Treatment and Diagnosis, National Cancer Institute**

5. REPORTER'S NAME, TITLE, AND INSTITUTION

**Howard Streicher, MD – Senior Investigator for Investigational Therapeutics 3, Investigational Drug Branch, CTEP, DCTD, NCI****John Wright, MD, Ph.D. – Associate Branch Chief for Investigational Therapeutics 2, Investigational Drug Branch, CTEP, DCTD, NCI**

6. PHONE NUMBER

**301-496-1196**

7. FAX NUMBER

**301-402-0428**

8. PROTOCOL NUMBER (AE#)

**S0777 (1628411)**

9. PATIENT IDENTIFICATION

**214171**

10. AGE

**35**

11. SEX

**Male**

12. DESCRIPTION OF ADVERSE EVENT

The patient was a 35-year-old male with multiple myeloma who died after becoming short of breath while on a phase 3 trial using the investigational agents lenalidomide in combination with bortezomib. He began investigational therapy with lenalidomide and bortezomib on January 16, 2009, and received the last dose of lenalidomide on February 22 (Cycle 2, Day 14), and the last dose of bortezomib on February 19, 2009 (Cycle 2, Day 11). On February 23, 2009, the patient developed dyspnea and was transported to the emergency room by ambulance. After arrival in the emergency room, he expired. No autopsy was performed. There is a reasonable possibility that the experience may have been caused by the drug. Additional information has been requested from the investigational site.

13. DOSE, ROUTE, AND SCHEDULE

**Cycle = 21 days****Lenalidomide 25 mg PO on days 1-14****Bortezomib: 1.3 mg/m<sup>2</sup> IVP on days 1, 4, 8, and 11**

14. DATES OF TREATMENT

The patient started investigational treatment on January 16, 2009, and received the last dose of lenalidomide on February 22 (Cycle 2, Day 14), and the last dose of bortezomib on February 19, 2009 (Cycle 2, Day 11).

15. ACCRUAL AND IND EXPERIENCE

Number of patients enrolled in NCI-sponsored clinical trials using lenalidomide = 1540, and bortezomib = 2706. Other incidences reported to the NCI through AdEERS as serious adverse events: 4 sudden deaths, 6 death NOS, and 62 incidents of dyspnea for lenalidomide; 8 sudden deaths, 11 death NOS, and 74 incidents of dyspnea for bortezomib.

16. COMMENTS

**Also administered on this protocol: Dexamethasone 20 mg PO on days 1, 2, 4, 5, 8, 9, 11, and 12; Last administered February 20, 2009; Aspirin 325 mg PO daily**

**AT THIS TIME, NO OTHER INFORMATION IS AVAILABLE. IF UPON FURTHER INVESTIGATION RELEVANT INFORMATION BECOMES AVAILABLE, THEN A FOLLOW-UP REPORT WILL BE SUBMITTED IN ACCORDANCE WITH 21CFR 312.32(d)(2).**

**DISCLAIMER per 21 CFR 312.32(e): THIS SAFETY REPORT DOES NOT NECESSARILY REFLECT A CONCLUSION OR ADMISSION BY THE CTEP IDB SENIOR INVESTIGATOR/ SPONSOR THAT THE INVESTIGATIONAL AGENT/THERAPY CAUSED OR CONTRIBUTED TO THE ADVERSE EXPERIENCE BEING REPORTED.**

0002